Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy
2023 ASCO Genitourinary Cancers Symposium
Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses new data from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The findings suggest that patients whose disease does not respond to bacillus Calmette-Guérin or who declined or were ineligible for a radical cystectomy may benefit from pembrolizumab monotherapy. (Abstract LBA442).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The cohort B of KEYNOTE-057 study investigated pembrolizumab monotherapy in patients with high-risk and non-muscle invasive disease, unresponsive to BCG. The 057 study is a multi-cohort study. The cohort A of the study included the patients with the carcinoma in situ component to with or without papillary disease, unresponsive to BCG who were ineligible for, or declined, radical cystectomy. Results from cohort A presented the clinical complete response rate at 3 months of 40%, with most of the complete responses maintained over time, and resulted in FDA approval of pembrolizumab in the CIS BCG unresponsive population.
The results of cohort B that have been presented at this meeting focused on a bit different patient population, represented by patients without any carcinoma in situ component, and with the only papillary pTa high-grade or any pT1 disease without CIS. This is a very special population for which we do not have any robust standard of care. This is the focus of the cohort B of the study. The design of the study was the same. Pembrolizumab monotherapy until 2 years every 3 weeks or until disease occurrence or progression with high-risk disease. The primary endpoint of this court was 12-month disease-free survival for high-risk disease. Secondary endpoints included the progression-free survival, disease-free survival for any disease occurrence, and the overall survival and quality of life parameters.
The main findings of the KEYNOTE-057 cohort B resulted in 12-month disease-free survival for high-risk disease of almost 43%, which sets among the most robust data already available with this special population. The progression-free survival to any stage progression or stage disease or death was 88%, and progression to muscle-invasive metastatic disease or death was a similar, 88%. There were no new safety signals, no treatment related death. Results, in terms of safety, were consistent with the already available data with pembrolizumab in various disease settings, including cohort A. Quality of life parameters and quality of life scores were maintained over time, were stable over time in patients who continue treatment with or without any recurrence.
So, how can we move forward with this data? Of course, the US FDA requires a randomized study in order to set new standards with newer therapies, and particularly systemic therapies in this special patient population. I think that the data from the cohort B of the study may allow us to re-discuss the need for doing a randomized study in this very difficult to treat population without any robust standard of care intravesical therapy, without any clinical trial option, because of the fact we that we currently lack robust data on standard of care therapies to compare with any newer therapies, intravesically or as a systemic therapy. So I think that the good point of this study is that it will likely generate a new discussion at [inaudible 00:03:21], including regulators, patient advocates, and physicians.
Related Videos
The ASCO Post Staff
Aristotelis Bamias, MD, of the National and Kapodistrian University of Athens, discusses results from the phase III IMvigor130 study, which suggest that atezolizumab monotherapy continues to show better tolerability vs chemotherapy for patients with untreated locally advanced or metastatic urothelial carcinoma. (Abstract LBA441).
The ASCO Post Staff
Matt D. Galsky, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses results from CheckMate 274, which investigated nivolumab compared with placebo in patients with bladder or upper urinary tract cancer, following radical surgery to remove invasive disease. (Abstract LBA443).
The ASCO Post Staff
Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, both of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss results from the retrospective UNITE study of biomarkers of response to the antibody-drug conjugate enfortumab vedotin-ejfv in patients with advanced urothelial carcinoma. Enfortumab vedotin is used widely in treatment-refractory disease, but there have been limited data available on biomarkers that may predict outcomes with this treatment. The UNITE study has now identified several potential biomarkers that need to be validated to help inform clinical decision-making and therapy sequencing. (Abstract 450).
The ASCO Post Staff
Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses study results showing that, the anti-PSMA (prostate-specific membrane antigen) monoclonal antibody J591 with ketoconazole and hydrocortisone, when radiolabeled with lutetium-177, leads to improved 18-month metastasis-free survival vs radiolabeling with indium-111 in patients with nonmetastatic (M0) castration-resistant prostate cancer. This supports the development of anti-PSMA radioimmunotherapy, although the optimal radionuclide and targeting agent are unknown. (Abstract LBA21).
The ASCO Post Staff
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discusses new data from the COSMIC-313 study of patients with advanced renal cell carcinoma of IMDC (International Metastatic RCC Database Consortium) intermediate or poor risk. Those who received cabozantinib instead of placebo with nivolumab and ipilimumab as first-line treatment seemed to experience improved progression-free survival. A subgroup analysis suggested the benefit was primarily in patients with an intermediate risk. Follow-up for overall survival is ongoing. (Abstract 605).
